Anaplastic Thyroid Carcinoma, Version 2.2015

Restricted access

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

  • 1.

    Howlader N, Noone A, Krapcho M. SEER Cancer Statistics Review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Bethesda, MD: National Cancer Institute; 2015. Available at: http://seer.cancer.gov/csr/1975_2012/.

    • Search Google Scholar
    • Export Citation
  • 2.

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010:1646.

  • 3.

    Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine Tumors. Cambridge: Blackwell Scientific Publications 1993:278333.

    • Search Google Scholar
    • Export Citation
  • 4.

    Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med 2004;351:17641771.

  • 5.

    Cooper DS, Doherty GM, Haugen BR. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:11671214.

    • Search Google Scholar
    • Export Citation
  • 6.

    Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med 1994;154:18381840.

    • Search Google Scholar
    • Export Citation
  • 7.

    Ron E, Lubin JH, Shore RE. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259277.

    • Search Google Scholar
    • Export Citation
  • 8.

    Schneider AB, Bekerman C, Leland J. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J Clin Endocrinol Metab 1997;82:40204027.

    • Search Google Scholar
    • Export Citation
  • 9.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:529.

  • 10.

    Jonklaas J, Nogueras-Gonzalez G, Munsell M. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 2012;97:E878887.

    • Search Google Scholar
    • Export Citation
  • 11.

    Stroup AM, Harrell CJ, Herget KA. Long-term survival in young women: hazards and competing risks after thyroid cancer. J Cancer Epidemiol 2012;2012:641372.

    • Search Google Scholar
    • Export Citation
  • 12.

    Altekruse S, Kosary C, Krapcho M. SEER Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute; 2010.

  • 13.

    SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute; 2009.

  • 14.

    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418428.

    • Search Google Scholar
    • Export Citation
  • 15.

    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:21642167.

  • 16.

    Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317322.

  • 17.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:929.

  • 18.

    Li N, Du XL, Reitzel LR. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid 2013;23:103110.

    • Search Google Scholar
    • Export Citation
  • 19.

    Wilhelm S. Evaluation of thyroid incidentaloma. Surg Clin North Am 2014;94:485497.

  • 20.

    Ito Y, Tomoda C, Uruno T. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 2004;28:11151121.

  • 21.

    Aschebrook-Kilfoy B, Grogan RH, Ward MH. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid 2013;23:10151021.

    • Search Google Scholar
    • Export Citation
  • 22.

    Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 2011;21:125134.

    • Search Google Scholar
    • Export Citation
  • 23.

    Yu GP, Li JC, Branovan D. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 2010;20:465473.

    • Search Google Scholar
    • Export Citation
  • 24.

    Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009;115:38013807.

    • Search Google Scholar
    • Export Citation
  • 25.

    Enewold L, Zhu K, Ron E. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 2009;18:784791.

    • Search Google Scholar
    • Export Citation
  • 26.

    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212236.

    • Search Google Scholar
    • Export Citation
  • 27.

    Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225249.

  • 28.

    Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453464.

    • Search Google Scholar
    • Export Citation
  • 29.

    Kebebew E, Greenspan FS, Clark OH. Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005;103:13301335.

  • 30.

    Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 1997;79:564573.

    • Search Google Scholar
    • Export Citation
  • 31.

    Smallridge RC, Ain KB, Asa SL. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22:11041139.

    • Search Google Scholar
    • Export Citation
  • 32.

    Moretti F, Farsetti A, Soddu S. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997;14:729740.

    • Search Google Scholar
    • Export Citation
  • 33.

    Maatouk J, Barklow TA, Zakaria W, Al-Abbadi MA. Anaplastic thyroid carcinoma arising in long-standing multinodular goiter following radioactive iodine therapy: report of a case diagnosed by fine needle aspiration. Acta Cytol 2009;53:581583.

    • Search Google Scholar
    • Export Citation
  • 34.

    Aldinger KA, Samaan NA, Ibanez M & Hill CS Jr. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978;41:22672275.

    • Search Google Scholar
    • Export Citation
  • 35.

    Keutgen XM, Sadowski SM, Kebebew E. Management of anaplastic thyroid cancer. Gland Surg 2015;4:4451.

  • 36.

    Thompson LD, Wieneke JA, Paal E. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001;91:505524.

    • Search Google Scholar
    • Export Citation
  • 37.

    Sherman SI. Anaplastic carcinoma: Clinical aspects. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd ed. Totowa, NJ: Humana Press; 2006:629632.

    • Search Google Scholar
    • Export Citation
  • 38.

    Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA Cancer J Clin 2009;59:99110.

  • 39.

    Baloch ZW, Cibas ES, Clark DP. The National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference: a summation. Cytojournal 2008;5:6.

    • Search Google Scholar
    • Export Citation
  • 40.

    Eilers SG, LaPolice P, Mukunyadzi P. Thyroid fine-needle aspiration cytology: performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non-GYN Assessment program thyroid fine-needle performance data. Cancer Cytopathol 2014;122:745750.

    • Search Google Scholar
    • Export Citation
  • 41.

    Yeh MW, Demircan O, Ituarte P, Clark OH. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid 2004;14:207215.

    • Search Google Scholar
    • Export Citation
  • 42.

    Asa SL, Bedard YC. Fine-needle aspiration cytology and histopathology. In: Clark OH, Noguchi S, eds. Thyroid Cancer: Diagnosis and Treatment. St Louis: Quality Medical Publishing; 2000:105126.

    • Search Google Scholar
    • Export Citation
  • 43.

    Seethala RR, Asa SL, Carty SE. Protocol for the examination of specimens from patients with carcinomas of the thyroid gland: based on AJCC/UICC TNM, 7th edition: Protocol web posting date: August 2014: College of American Pathologists; 2014. Available at: http://www.cap.org/web/home/resources/cancer-reporting-tools/cancer-protocol-templates.

    • Search Google Scholar
    • Export Citation
  • 44.

    Takashima S, Morimoto S, Ikezoe J. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990;154:10791085.

  • 45.

    Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008;37:525538, xi.

  • 46.

    Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg 2011;19:113118.

  • 47.

    Untch BR & Olson JA Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15:661679, x.

  • 48.

    Shaha AR. Airway management in anaplastic thyroid carcinoma. Laryngoscope 2008;118:11951198.

  • 49.

    Venkatesh YS, Ordonez NG, Schultz PN. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990;66:321330.

  • 50.

    Sugitani I, Miyauchi A, Sugino K. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012;36:12471254.

    • Search Google Scholar
    • Export Citation
  • 51.

    Akaishi J, Sugino K, Kitagawa W. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011;21:11831189.

    • Search Google Scholar
    • Export Citation
  • 52.

    Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:8388.

  • 53.

    McIver B, Hay ID, Giuffrida DF. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:10281034.

  • 54.

    Burge MR, Zeise TM, Johnsen MW. Risks of complication following thyroidectomy. J Gen Intern Med 1998;13:2431.

  • 55.

    Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:8893.

  • 56.

    Pattou F, Combemale F, Fabre S. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg 1998;22:718724.

  • 57.

    Hassanain M, Wexler M. Conservative management of well-differentiated thyroid cancer. Can J Surg 2010;53:109118.

  • 58.

    Sosa JA, Bowman HM, Tielsch JM. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320330.

    • Search Google Scholar
    • Export Citation
  • 59.

    Dumke AK, Pelz T, Vordermark D. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol 2014;9:90.

  • 60.

    Brierley J, Sherman E. The role of external beam radiation and targeted therapy in thyroid cancer. Semin Radiat Oncol 2012;22:254262.

  • 61.

    Burnison CM, Lim S. Multimodal approach to anaplastic thyroid cancer. Oncology (Williston Park) 2012;26:378384, 390.

  • 62.

    Wang Y, Tsang R, Asa S. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006;107:17861792.

    • Search Google Scholar
    • Export Citation
  • 63.

    Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:36373642.

    • Search Google Scholar
    • Export Citation
  • 64.

    De Crevoisier R, Baudin E, Bachelot A. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:11371143.

    • Search Google Scholar
    • Export Citation
  • 65.

    Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:23722375.

    • Search Google Scholar
    • Export Citation
  • 66.

    Mohebati A, Dilorenzo M, Palmer F. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol 2014;21:16651670.

  • 67.

    Derbel O, Limem S, Segura-Ferlay C. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011;11:469.

  • 68.

    Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004;93:272277.

  • 69.

    Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012;97:25662572.

  • 70.

    Bhatia A, Rao A, Ang KK. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 2010;32:829836.

  • 71.

    Sun XS, Sun SR, Guevara N. Chemoradiation in anaplastic thyroid carcinomas. Crit Rev Oncol Hematol 2013;86:290301.

  • 72.

    Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother 2011;15:555559.

    • Search Google Scholar
    • Export Citation
  • 73.

    Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT): Contents. J ICRU 2010;10:NP.

  • 74.

    Sosa JA, Balkissoon J, Lu SP. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery 2012;152:10781087.

    • Search Google Scholar
    • Export Citation
  • 75.

    Swaak-Kragten AT, de Wilt JH, Schmitz PI. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol 2009;92:100104.

    • Search Google Scholar
    • Export Citation
  • 76.

    Lowe NM, Loughran S, Slevin NJ, Yap BK. Anaplastic thyroid cancer: the addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival: a single centre experience and review of the literature. Scientific World J 2014;2014:674583.

    • Search Google Scholar
    • Export Citation
  • 77.

    Higashiyama T, Ito Y, Hirokawa M. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010;20:714.

    • Search Google Scholar
    • Export Citation
  • 78.

    Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715726.

  • 79.

    Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587594.

    • Search Google Scholar
    • Export Citation
  • 80.

    Bible KC, Suman VJ, Menefee ME. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012;97:31793184.

    • Search Google Scholar
    • Export Citation
  • 81.

    Ha HT, Lee JS, Urba S. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010;20:975980.

  • 82.

    Savvides P, Nagaiah G, Lavertu P. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013;23:600604.

    • Search Google Scholar
    • Export Citation
  • 83.

    Keefe SM, Troxel AB, Rhee S. Phase II trial of sorafenib in patients with advanced thyroid cancer [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 5562.

    • Search Google Scholar
    • Export Citation
  • 84.

    Brose MS, Nutting CM, Sherman SI. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349.

    • Search Google Scholar
    • Export Citation
  • 85.

    Antonelli A, Fallahi P, Ulisse S. New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem 2012;12:8793.

  • 86.

    Perri F, Lorenzo GD, Scarpati GD, Buonerba C. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011;2:150157.

    • Search Google Scholar
    • Export Citation
  • 87.

    Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008;20:1924.

    • Search Google Scholar
    • Export Citation
  • 88.

    Mooney CJ, Nagaiah G, Fu P. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009;19:233240.

    • Search Google Scholar
    • Export Citation
  • 89.

    Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:1744.

    • Search Google Scholar
    • Export Citation
  • 90.

    Sosa JA, Elisei R, Jarzab B. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 2014;24:232240.

    • Search Google Scholar
    • Export Citation
  • 91.

    Foote RL, Molina JR, Kasperbauer JL. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21:2530.

    • Search Google Scholar
    • Export Citation
  • 92.

    Nagaiah G, Hossain A, Mooney CJ. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011:542358.

  • 93.

    Siironen P, Hagstrom J, Maenpaa HO. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 2010;79:400408.

    • Search Google Scholar
    • Export Citation
  • 94.

    Brignardello E, Gallo M, Baldi I. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 2007;156:425430.

    • Search Google Scholar
    • Export Citation
  • 95.

    Yau T, Lo CY, Epstein RJ. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol 2008;15:25002505.

    • Search Google Scholar
    • Export Citation
  • 96.

    Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 2002;25:442446.

    • Search Google Scholar
    • Export Citation
  • 97.

    Chou A, Fraser S, Toon CW. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 2015;39:652659.

    • Search Google Scholar
    • Export Citation
  • 98.

    Park G, Kim TH, Lee HO. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer. Endocr Relat Cancer 2015;22:5563.

    • Search Google Scholar
    • Export Citation
  • 99.

    Perot G, Soubeyran I, Ribeiro A. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One 2014;9:e87170.

  • 100.

    Kelly LM, Barila G, Liu P. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014;111:42334238.

    • Search Google Scholar
    • Export Citation
  • 101.

    Kunstman JW, Juhlin CC, Goh G. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 2015;24:23182329.

    • Search Google Scholar
    • Export Citation
  • 102.

    Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013;368:684685.

  • 103.

    Takano T, Ito Y, Hirokawa M. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 2007;96:15491553.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 448 310 17
PDF Downloads 127 103 24
EPUB Downloads 0 0 0